Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus is a chronic, autoimmune disease in which the body’s own immune system generates autoreactive lymphocytes (white blood cells) and autoantibodies that mistakenly attack healthy tissues. This can lead to swelling, pain, and damage in virtually any part of the body, including the skin, joints, kidneys, heart, lungs, and brain.
SLE symptoms range in severity and vary widely, and from fatigue, rash and intermittent arthralgias to life-threatening vasculitis and organ system failure. Nephritis is the most common organ system threat and fatigue and cognitive dysfunction are the most common disabling manifestation.
Symptoms can come and go in cycles consisting of flares and remission. Disease relapses may lead to cumulative damage and organ failure.
Unmet need
There is a high unmet need in SLE. Steroids considered first-line treatment, but are not a long-term solution,
and many patients who receive approved therapies relapse. Rituximab is not approved for SLE, but is a
mainstay of treatment, underscoring the need for more effective therapies.
240k patients in
the US alone
~50% patients on approved
biologics relapse
CD19 CAR T therapy modality limits
broad utility and
patient access
How budoprutug may be able to help
B cell depleting therapies such as budoprutug are a promising potential treatment approach for SLE because they work to eliminate the problematic B cells that produce the autoantibodies that cause the disease.
Budoprutug targets CD19, which has broad expression across many types of B cells, including autoantibody producing cells.
Support and Resources
If you or someone you love is living with Systemic Lupus Erythematosus (SLE), there are many resources available to help you learn more, connect with others, and find support. These trusted organizations provide education, advocacy, and community for people affected by lupus.
